Compare pathways by evidence, regulatory status, cost and access, travel burden, complexity, and what providers disclose — and what they don’t.
Condition-first navigator
Not sure which treatment category matters? Start with the problem you’re trying to solve.
Explore by pathway
Understand product type, evidence maturity, regulatory context and provider documentation before comparing availability. These pathways are not interchangeable.
Cell source, processing and jurisdiction
In the United States most culture-expanded cell products are regulated as drugs and require FDA authorisation. Availability outside clinical trials differs by jurisdiction.
Acellular products; no FDA-approved products
The FDA has issued public safety notifications about unapproved exosome products. Regulatory status varies significantly by country.
Compound-specific approval and evidence
Several peptides are restricted, compounded, or unapproved for human use depending on jurisdiction.
Preparation method and indication matter
Commonly performed as a same-day autologous procedure. Coverage and classification differ by jurisdiction and payer.
How Navigator works
Browse by condition, destination, treatment and transparency.
Review clinics side by side. Missing information stays visibly missing.
Inspect sources, score breakdowns, documentation status and questions to ask.
Featured destinations
Explore destination context from published provider profiles. Presence here is not an endorsement.
Independent by design
Educational information only — not medical advice, diagnosis or treatment. Provider profiles may include clinic-supplied claims, independently verified facts, pending items and information not disclosed. Source and verification status are shown where available. Sponsored placement never affects scoring.